NSE · IPCALAB.NS
Ipca Laboratories Limited
₹1,929.80+₹3.60 (+0.19%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.31% below the high.
Loading market information…
NSE · ERIS.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 08:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Eris Lifesciences Limited’s quoted price sits in the lower half of its reported 52-week range, 32.93% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Eris Lifesciences Limited’s forward annual dividend is ₹7.35 per share, paid annual. The forward yield is 0.63% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Eris Lifesciences Limited’s next earnings report is currently expected on Jan 22, 2027, with estimated earnings per share of ₹10.40. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Eris Lifesciences Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Eris Lifesciences Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of medicinal products throughout the country. The company provides a comprehensive range of branded formulations, catering to a wide spectrum of therapeutic areas. These encompass cardiovascular health, anti-diabetic treatments, anti-infectives, antipyretics, vitamin/nutrient supplements, gastroenterology, respiratory care, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, alongside services in in-vitro fertilization, cosmetology, and dermatology. Founded in 2007, Eris Lifesciences Limited is headquartered in Ahmedabad, India.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2026 | Aug 5, 2025 | ₹8.70+2.11% vs estimate | ₹7.73B-4.04% vs estimate |
|---|
| Q4 2025 | May 19, 2025 | ₹6.88-1.71% vs estimate | ₹7.03B-6.56% vs estimate |
|---|
| Q3 2025 | Feb 4, 2025 | ₹6.10-7.15% vs estimate | ₹7.28B-2.6% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,929.80+₹3.60 (+0.19%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.31% below the high.
₹6,350.50+₹51.50 (+0.82%)
AstraZeneca Pharma India Limited’s quoted price sits in the lower half of its reported 52-week range, 35.52% below the high.
₹798.35+₹3.50 (+0.44%)
Alembic Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 20.01% below the high.
₹924.30-₹21.70 (-2.29%)
Jubilant Pharmova Limited’s quoted price sits in the lower half of its reported 52-week range, 21.87% below the high.
₹309.95-₹5.40 (-1.71%)
Marksans Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 11.68% below the high.
₹1,027.50-₹70.00 (-6.38%)
Strides Pharma Science Limited’s quoted price sits in the upper half of its reported 52-week range, 18.51% below the high.
₹648.40-₹32.50 (-4.77%)
Bliss GVS Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 12.57% below the high.
₹2,622.00-₹381.80 (-12.71%)
RPG Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 16.17% below the high.
